新冠專題
COVID-19
Development of a thermostable SARS-CoV-2 variant-d bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants
2022-09-20
999+
最新文獻
上一篇：Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine SCTV01C in unvaccinated adults: A randomized double-blinded placebo-controlled phase I clinical trial
下一篇：A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
最新資訊
-
A spike-trimer protein-d tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants
2022-12-30 -
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine SCTV01C in adults previously vaccinated with mRNA vaccine: A randomized double-blind placebo-controlled phase 1/2 clinical trial
2022-12-05 -
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized double-blind placebo-controlled phase 1/2 clinical trial
2022-12-09 -
Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine SCTV01C in unvaccinated adults: A randomized double-blinded placebo-controlled phase I clinical trial
2022-11-17